Spero Therapeutics (SPRO)
Spero Therapeutics on one page: short interest, daily short volume, fails to deliver, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
841K
Short interest
settlement 2026-10-15
1.5
Days to cover
+0.5 days vs prior
42.2%
Short share of volume
2026-11-03
1,111
Fails to deliver
settlement 2026-10-13
Thu 12 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-03.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in SPRO is 840,529 shares, down 135,959 shares over the last month. Over the last 48 readings it ranged from 315,715 shares (15 October 2025) to 3,476,335 shares (30 May 2025). At the reported average volume of 558K shares a day that is 1.5 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/spro" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 840,529 | +5.8% | 558,471 | 1.51 |
| 2026-09-30 | 794,509 | -18.6% | 1,144,097 | 1.00 |
| 2026-09-15 | 976,488 | -19.3% | 319,458 | 3.06 |
| 2026-08-31 | 1,210,417 | -16.3% | 409,813 | 2.95 |
| 2026-08-14 | 1,445,879 | -4.5% | 760,511 | 1.90 |
| 2026-07-31 | 1,513,354 | -28.4% | 2,524,691 | 1.00 |
| 2026-07-15 | 2,113,935 | -26.2% | 1,649,627 | 1.28 |
| 2026-06-30 | 2,864,850 | +56.4% | 2,752,049 | 1.04 |
| 2026-06-15 | 1,831,713 | +7.3% | 813,375 | 2.25 |
| 2026-05-29 | 1,706,545 | +3.6% | 868,868 | 1.96 |
| 2026-05-15 | 1,647,297 | +39.6% | 630,469 | 2.61 |
| 2026-04-30 | 1,179,702 | +59.9% | 385,421 | 3.06 |
| 2026-04-15 | 737,720 | +21.9% | 531,221 | 1.39 |
| 2026-03-31 | 605,311 | +12.6% | 325,576 | 1.86 |
| 2026-03-13 | 537,411 | -6.4% | 312,939 | 1.72 |
| 2026-02-27 | 574,027 | -19.8% | 270,567 | 2.12 |
| 2026-02-13 | 715,694 | -24.0% | 426,955 | 1.68 |
| 2026-01-30 | 941,659 | -9.4% | 234,710 | 4.01 |
| 2026-01-15 | 1,039,613 | +9.8% | 234,737 | 4.43 |
| 2025-12-31 | 946,767 | -10.3% | 245,736 | 3.85 |
| 2025-12-15 | 1,056,013 | +27.9% | 300,621 | 3.51 |
| 2025-11-28 | 825,698 | +34.1% | 385,653 | 2.14 |
| 2025-11-14 | 615,735 | +29.3% | 584,142 | 1.05 |
| 2025-10-31 | 476,137 | +50.8% | 1,550,785 | 1.00 |
| 2025-10-15 | 315,715 | -42.5% | 535,376 | 1.00 |
| 2025-09-30 | 549,473 | +19.8% | 266,105 | 2.06 |
| 2025-09-15 | 458,620 | -9.0% | 347,363 | 1.32 |
| 2025-08-29 | 503,998 | -45.6% | 371,999 | 1.35 |
| 2025-08-15 | 927,158 | -32.8% | 1,013,636 | 1.00 |
| 2025-07-31 | 1,379,953 | +13.4% | 614,381 | 2.25 |
| 2025-07-15 | 1,217,101 | -28.3% | 1,000,730 | 1.22 |
| 2025-06-30 | 1,697,497 | +5.3% | 1,373,351 | 1.24 |
| 2025-06-13 | 1,612,678 | -53.6% | 2,786,502 | 1.00 |
| 2025-05-30 | 3,476,335 | +446.0% | 21,430,481 | 1.00 |
| 2025-05-15 | 636,730 | -1.3% | 113,126 | 5.63 |
| 2025-04-30 | 645,163 | -19.5% | 78,377 | 8.23 |
| 2025-04-15 | 801,304 | +60.9% | 248,851 | 3.22 |
| 2025-03-31 | 498,066 | +13.9% | 144,395 | 3.45 |
| 2025-03-14 | 437,248 | +3.0% | 94,977 | 4.60 |
| 2025-02-28 | 424,739 | -1.1% | 94,404 | 4.50 |
| 2025-02-14 | 429,588 | +14.0% | 333,471 | 1.29 |
| 2025-01-31 | 376,788 | +6.4% | 188,424 | 2.00 |
| 2025-01-15 | 354,105 | -14.2% | 225,857 | 1.57 |
| 2024-12-31 | 412,644 | -8.6% | 309,053 | 1.34 |
| 2024-12-13 | 451,216 | -8.6% | 160,636 | 2.81 |
| 2024-11-29 | 493,832 | -9.7% | 265,888 | 1.86 |
| 2024-11-15 | 546,831 | -12.5% | 319,556 | 1.71 |
| 2024-10-31 | 625,191 | +61.5% | 417,643 | 1.50 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 3 November 2026, the short share of SPRO volume is 42.2%, up 6.3 points over the last five sessions. Over the last 30 readings it ranged from 14.2% (21 October 2026) to 50.5% (30 October 2026). The latest reading is 9.1 points above the 30-session average of 33.2%, on 139K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-03 | 59K | 139K | 42.2% | 500 |
| 2026-11-02 | 84K | 275K | 30.6% | 0 |
| 2026-10-30 | 81K | 161K | 50.5% | 0 |
| 2026-10-29 | 42K | 104K | 40.6% | 0 |
| 2026-10-28 | 34K | 143K | 23.6% | 0 |
| 2026-10-27 | 95K | 265K | 35.9% | 0 |
| 2026-10-26 | 134K | 302K | 44.2% | 0 |
| 2026-10-23 | 83K | 166K | 50.0% | 0 |
| 2026-10-22 | 43K | 130K | 33.0% | 0 |
| 2026-10-21 | 15K | 104K | 14.2% | 0 |
| 2026-10-20 | 89K | 358K | 24.9% | 0 |
| 2026-10-19 | 56K | 126K | 44.9% | 0 |
| 2026-10-16 | 38K | 185K | 20.6% | 0 |
| 2026-10-15 | 53K | 141K | 37.6% | 0 |
| 2026-10-14 | 100K | 274K | 36.3% | 50 |
| 2026-10-13 | 45K | 130K | 34.4% | 0 |
| 2026-10-12 | 53K | 185K | 28.6% | 0 |
| 2026-10-09 | 65K | 219K | 29.5% | 0 |
| 2026-10-08 | 44K | 185K | 23.9% | 0 |
| 2026-10-07 | 20K | 133K | 15.0% | 0 |
| 2026-10-06 | 100K | 204K | 48.9% | 0 |
| 2026-10-05 | 107K | 229K | 46.7% | 319 |
| 2026-10-02 | 94K | 285K | 32.9% | 500 |
| 2026-10-01 | 250K | 513K | 48.6% | 0 |
| 2026-09-30 | 27K | 85K | 31.6% | 0 |
| 2026-09-29 | 65K | 173K | 37.4% | 0 |
| 2026-09-28 | 33K | 132K | 25.3% | 0 |
| 2026-09-25 | 27K | 166K | 16.2% | 0 |
| 2026-09-24 | 54K | 225K | 24.0% | 0 |
| 2026-09-23 | 155K | 690K | 22.4% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 13 October 2026, the fails-to-deliver balance in SPRO is 1,111 shares, down 48,889 shares over the last settlement date. Over the last 30 readings it ranged from 5 shares (29 July 2026) to 55,493 shares (20 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-13 | 1,111 | $1.18 | $1K |
| 2026-10-02 | 50,000 | $1.26 | $63K |
| 2026-08-25 | 15,213 | $1.22 | $19K |
| 2026-08-20 | 17 | $1.23 | $21 |
| 2026-08-12 | 742 | $1.23 | $913 |
| 2026-08-11 | 28 | $1.23 | $34 |
| 2026-08-10 | 26,872 | $1.26 | $34K |
| 2026-08-06 | 12,711 | $1.26 | $16K |
| 2026-08-04 | 38,252 | $1.15 | $44K |
| 2026-08-03 | 34 | $1.17 | $40 |
| 2026-07-29 | 5 | $1.20 | $6 |
| 2026-07-24 | 5,270 | $1.16 | $6K |
| 2026-07-20 | 55,493 | $1.58 | $88K |
| 2026-07-17 | 409 | $1.57 | $642 |
| 2026-07-14 | 10,521 | $2.18 | $23K |
| 2026-07-13 | 15,259 | $2.10 | $32K |
| 2026-07-10 | 10,000 | $2.12 | $21K |
| 2026-07-01 | 171 | $2.21 | $378 |
| 2026-06-30 | 47,602 | $2.26 | $108K |
| 2026-06-29 | 730 | $2.26 | $2K |
| 2026-06-24 | 1,011 | $2.15 | $2K |
| 2026-06-22 | 9,572 | $2.28 | $22K |
| 2026-06-18 | 3,755 | $2.11 | $8K |
| 2026-06-17 | 20,293 | $2.77 | $56K |
| 2026-06-16 | 5,631 | $2.91 | $16K |
| 2026-06-15 | 23,494 | $2.85 | $67K |
| 2026-06-12 | 5,678 | $2.70 | $15K |
| 2026-06-11 | 15,911 | $2.54 | $40K |
| 2026-06-08 | 11,224 | $2.82 | $32K |
| 2026-05-29 | 16,734 | $2.90 | $49K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for SPRO in the last 90 days. The most recent filings are listed below. Latest filing: Zack Debra (Chief Medical Officer) on 2026-08-03.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-03 | Zack Debra | Chief Medical Officer | Grant | 162K | $0.00 | $0 | 162K |
| 2026-06-23 | Pottage John C Jr | Director | Grant | 10K | $0.00 | $0 | 85K |
| 2026-06-23 | Jackson Scott Thomas | Director | Grant | 10K | $0.00 | $0 | 85K |
| 2026-06-23 | THOMAS FRANK E | Director | Grant | 10K | $0.00 | $0 | 85K |
| 2026-06-23 | VINK PATRICK V.J.J. | Director | Grant | 10K | $0.00 | $0 | 85K |
| 2026-06-23 | Smith Cynthia | Director | Grant | 10K | $0.00 | $0 | 85K |
| 2026-06-23 | Tregoning Kathleen | Director | Grant | 10K | $0.00 | $0 | 85K |
| 2026-06-23 | Deshpande Milind | Director | Grant | 10K | $0.00 | $0 | 101K |
| 2026-05-04 | Rajavelu Esther | See Remarks | Sell | 25K | $2.51 | $63K | 987K |
| 2026-02-06 | Rajavelu Esther | See Remarks | Sell | 51K | $2.36 | $120K | 1.0M |
| 2026-02-06 | Rajavelu Esther | See Remarks | Sell | 37K | $2.36 | $88K | 1.1M |
| 2026-02-06 | Keutzer Timothy | Chief Operating Officer | Sell | 19K | $2.36 | $44K | 743K |
| 2026-02-04 | Keutzer Timothy | Chief Operating Officer | Sell | 3K | $2.24 | $8K | 761K |
| 2026-02-03 | Keutzer Timothy | Chief Operating Officer | Sell | 24K | $2.14 | $52K | 765K |
| 2026-02-02 | Rajavelu Esther | See Remarks | Sell | 18K | $2.20 | $41K | 1.1M |
| 2026-02-02 | Rajavelu Esther | See Remarks | Grant | 249K | $0.00 | $0 | 1.1M |
| 2026-02-02 | Keutzer Timothy | Chief Operating Officer | Sell | 19K | $2.20 | $42K | 789K |
| 2026-02-02 | Keutzer Timothy | Chief Operating Officer | Grant | 68K | $0.00 | $0 | 808K |
| 2025-11-07 | Rajavelu Esther | See Remarks | Sell | 40K | $2.37 | $95K | 869K |
| 2025-08-28 | Mahadevia Ankit | Director | Sell | 7K | $1.97 | $13K | 703K |
| 2025-08-28 | Keutzer Timothy | Chief Operating Officer | Sell | 2K | $1.97 | $3K | 740K |
| 2025-06-12 | VINK PATRICK V.J.J. | Director | Grant | 20K | $0.00 | $0 | 75K |
| 2025-06-12 | THOMAS FRANK E | Director | Grant | 20K | $0.00 | $0 | 75K |
| 2025-06-12 | Tregoning Kathleen | Director | Grant | 20K | $0.00 | $0 | 75K |
| 2025-06-12 | Smith Cynthia | Director | Grant | 20K | $0.00 | $0 | 75K |
| 2025-06-12 | Pottage John C Jr | Director | Grant | 20K | $0.00 | $0 | 75K |
| 2025-06-12 | Mahadevia Ankit | Director | Grant | 20K | $0.00 | $0 | 710K |
| 2025-06-12 | Jackson Scott Thomas | Director | Grant | 20K | $0.00 | $0 | 75K |
| 2025-06-12 | Deshpande Milind | Director | Grant | 20K | $0.00 | $0 | 91K |
| 2025-05-02 | Rajavelu Esther | See Remarks | Grant | 185K | $0.00 | $0 | 910K |
| 2025-02-05 | Mahadevia Ankit | Director | Sell | 55K | $0.78 | $43K | 690K |
| 2025-02-05 | Mahadevia Ankit | Director | Sell | 14K | $0.78 | $11K | 745K |
| 2025-02-05 | Shukla Sath | CEO & President | Sell | 6K | $0.78 | $5K | 1.9M |
| 2025-02-05 | Shukla Sath | CEO & President | Sell | 43K | $0.78 | $33K | 1.8M |
| 2025-02-05 | Shukla Sath | CEO & President | Sell | 106K | $0.78 | $83K | 1.7M |
| 2025-02-05 | Rajavelu Esther | CFO & CBO | Sell | 21K | $0.78 | $16K | 725K |
| 2025-02-05 | Keutzer Timothy | Chief Operating Officer | Sell | 4K | $0.78 | $3K | 794K |
| 2025-02-05 | Keutzer Timothy | Chief Operating Officer | Sell | 28K | $0.78 | $22K | 766K |
| 2025-02-05 | Keutzer Timothy | Chief Operating Officer | Sell | 25K | $0.78 | $19K | 741K |
| 2025-02-03 | Shukla Sath | CEO & President | Grant | 751K | $0.00 | $0 | 1.9M |
| 2025-02-03 | Rajavelu Esther | CFO & CBO | Grant | 266K | $0.00 | $0 | 645K |
| 2025-02-03 | Rajavelu Esther | CFO & CBO | Grant | 100K | $0.00 | $0 | 745K |
| 2025-02-03 | Keutzer Timothy | Chief Operating Officer | Grant | 266K | $0.00 | $0 | 798K |
| 2024-11-08 | Rajavelu Esther | CFO & CBO | Sell | 17K | $1.30 | $22K | 379K |
| 2024-11-07 | Rajavelu Esther | CFO & CBO | Sell | 23K | $1.31 | $31K | 397K |
| 2024-08-27 | Shukla Sath | CEO & President | Sell | 3K | $1.35 | $4K | 1.1M |
| 2024-08-27 | Keutzer Timothy | Chief Operating Officer | Sell | 2K | $1.35 | $3K | 532K |
| 2024-08-27 | Mahadevia Ankit | Director | Sell | 6K | $1.35 | $8K | 759K |
| 2024-08-05 | Shukla Sath | CEO and President | Sell | 18K | $1.31 | $23K | 1.1M |
| 2024-08-02 | Shukla Sath | CEO and President | Sell | 15K | $1.32 | $20K | 1.2M |
| 2024-05-29 | Pottage John C Jr | Director | Grant | 20K | $0.00 | $0 | 55K |
| 2024-05-29 | THOMAS FRANK E | Director | Grant | 20K | $0.00 | $0 | 55K |
| 2024-05-29 | Smith Cynthia | Director | Grant | 20K | $0.00 | $0 | 55K |
| 2024-05-29 | VINK PATRICK V.J.J. | Director | Grant | 20K | $0.00 | $0 | 55K |
| 2024-05-29 | Tregoning Kathleen | Director | Grant | 20K | $0.00 | $0 | 55K |
| 2024-05-29 | Mahadevia Ankit | Director | Grant | 20K | $0.00 | $0 | 765K |
| 2024-05-29 | Jackson Scott Thomas | Director | Grant | 20K | $0.00 | $0 | 55K |
| 2024-05-29 | Deshpande Milind | Director | Grant | 20K | $0.00 | $0 | 71K |
| 2024-02-05 | Shukla Sath | CEO and President | Sell | 45K | $1.45 | $65K | 1.2M |
| 2024-02-02 | Shukla Sath | CEO and President | Sell | 31K | $1.37 | $42K | 1.2M |
| 2024-02-02 | HAMED KAMAL | Chief Medical Officer | Sell | 28K | $1.37 | $38K | 788K |
| 2024-02-02 | JOSEPH TAMARA L | Chief Legal Officer | Sell | 31K | $1.37 | $42K | 532K |
| 2024-02-02 | Mahadevia Ankit | Director | Sell | 64K | $1.37 | $87K | 745K |
| 2024-02-02 | Keutzer Timothy | Chief Operating Officer | Sell | 31K | $1.36 | $42K | 534K |
| 2024-02-01 | Shukla Sath | CEO and President | Grant | 680K | $0.00 | $0 | 1.3M |
| 2024-02-01 | Rajavelu Esther | See Remarks | Grant | 120K | $0.00 | $0 | 420K |
| 2024-02-01 | HAMED KAMAL | Chief Medical Officer | Grant | 240K | $0.00 | $0 | 816K |
| 2024-02-01 | JOSEPH TAMARA L | Chief Legal Officer | Grant | 240K | $0.00 | $0 | 563K |
| 2024-02-01 | Keutzer Timothy | Chief Operating Officer | Grant | 240K | $0.00 | $0 | 565K |
| 2023-11-13 | Rajavelu Esther | See Remarks | Grant | 300K | $0.00 | $0 | 300K |
| 2023-10-05 | Mahadevia Ankit | Director | Grant | 20K | $0.00 | $0 | 809K |
| 2023-10-05 | Jackson Scott Thomas | Director | Grant | 20K | $0.00 | $0 | 35K |
| 2023-10-05 | VINK PATRICK V.J.J. | Director | Grant | 20K | $0.00 | $0 | 35K |
| 2023-10-05 | Tregoning Kathleen | Director | Grant | 20K | $0.00 | $0 | 35K |
| 2023-10-05 | Deshpande Milind | Director | Grant | 20K | $0.00 | $0 | 51K |
| 2023-10-05 | THOMAS FRANK E | Director | Grant | 20K | $0.00 | $0 | 35K |
| 2023-10-05 | Smith Cynthia | Director | Grant | 20K | $0.00 | $0 | 35K |
| 2023-10-05 | Pottage John C Jr | Director | Grant | 20K | $0.00 | $0 | 35K |
| 2023-09-13 | HAMED KAMAL | Chief Medical Officer | Sell | 39K | $1.27 | $50K | 576K |
| 2023-08-29 | Shukla Sath | CEO and President | Sell | 4K | $1.30 | $5K | 573K |
| 2023-08-28 | Shukla Sath | CEO and President | Sell | 2K | $1.26 | $2K | 577K |
| 2023-08-28 | Mahadevia Ankit | Director | Sell | 9K | $1.26 | $11K | 789K |
| 2023-08-28 | JOSEPH TAMARA L | Chief Legal Officer | Sell | 2K | $1.26 | $2K | 323K |
| 2023-08-28 | Keutzer Timothy | Chief Development Officer | Sell | 2K | $1.26 | $2K | 325K |
| 2023-08-01 | Shukla Sath | CEO and President | Grant | 266K | $0.00 | $0 | 579K |
| 2023-06-12 | HAMED KAMAL | Chief Medical Officer | Grant | 140K | $0.00 | $0 | 616K |
| 2023-02-03 | Mahadevia Ankit | CEO and President | Sell | 12K | $1.81 | $22K | 798K |
| 2023-02-02 | Shukla Sath | Chief Financial Officer | Sell | 10K | $1.83 | $17K | 313K |
| 2023-02-02 | JOSEPH TAMARA L | Chief Legal Officer | Sell | 3K | $1.86 | $6K | 325K |
| 2023-02-02 | Keutzer Timothy | Chief Operating Officer | Sell | 3K | $1.86 | $6K | 327K |
| 2023-02-01 | Mahadevia Ankit | CEO and President | Grant | 532K | $0.00 | $0 | 810K |
| 2023-02-01 | HAMED KAMAL | Chief Medical Officer | Grant | 266K | $0.00 | $0 | 476K |
| 2023-02-01 | Shukla Sath | Chief Financial Officer | Grant | 266K | $0.00 | $0 | 322K |
| 2023-02-01 | JOSEPH TAMARA L | Chief Legal Officer | Grant | 266K | $0.00 | $0 | 328K |
| 2023-02-01 | Keutzer Timothy | Chief Operating Officer | Grant | 266K | $0.00 | $0 | 331K |
| 2022-09-22 | Aquilo Capital Management, LLC | TenPercentOwner | Sell | 1.3M | $2.25 | $3.0M | 4.0M |
| 2022-09-22 | Aquilo Capital Management, LLC | TenPercentOwner | Sell | 566K | $2.25 | $1.3M | 3.4M |
| 2022-09-15 | VINK PATRICK V.J.J. | Director | Grant | 15K | $0.00 | $0 | 15K |
| 2022-09-15 | Tregoning Kathleen | Director | Grant | 15K | $0.00 | $0 | 15K |
| 2022-09-15 | THOMAS FRANK E | Director | Grant | 15K | $0.00 | $0 | 15K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
13F holders
Tracked managers holding SPRO at their latest 13F. JSON4 of the 30 tracked managers held SPRO at their latest 13F, $3.2M in total at quarter-end prices. Renaissance Technologies is the largest at $2.1M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 948K | $2.1M | 0.00% | -241K |
| Two Sigma Investments | 2026-06-30 | 383K | $846K | 0.00% | -503K |
| Point72 Asset Management | 2026-06-30 | 104K | $231K | 0.00% | +45K |
| Millennium Management | 2026-06-30 | 19K | $43K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Spero Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Spero Therapeutics (SPRO), SEC CIK 1701108, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-03.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-05-13.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-08-03.JSON and CSV
- Company record
- EDGAR filing index for CIK 1701108Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of SPRO is sold short?
840,529 shares were held short at the 2026-10-15 settlement, 1.5 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is SPRO's daily short volume?
On 2026-11-03, 58,681 of the 138,951 SPRO shares reported to FINRA were sold short, 42.2% of the day's reported volume. Short volume is a flow for one day, not a position.
Does SPRO have fails to deliver?
The SEC's latest file shows 1,111 SPRO shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.
Are SPRO insiders buying or selling?
No open-market insider trades were reported for SPRO in the last 90 days. The most recent filings are listed below. Latest filing: Zack Debra (Chief Medical Officer) on 2026-08-03.
Which tracked 13F managers own SPRO?
4 of the 30 tracked 13F managers held SPRO shares at their latest filing, $3.2M in all. The largest: Renaissance Technologies (948K shares, $2.1M), Two Sigma Investments (383K shares, $846K), Steve Cohen's Point72 Asset Management (104K shares, $231K), Izzy Englander's Millennium Management (19K shares, $43K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.